Dynamic Technology Lab Private Ltd acquired a new stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 2,023 shares of the specialty pharmaceutical company’s stock, valued at approximately $296,000.

Several other institutional investors and hedge funds have also modified their holdings of the company. FMR LLC lifted its holdings in shares of Jazz Pharmaceuticals by 11.4% during the 2nd quarter. FMR LLC now owns 8,290,410 shares of the specialty pharmaceutical company’s stock valued at $1,289,159,000 after purchasing an additional 849,348 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 3.4% during the 2nd quarter. Vanguard Group Inc. now owns 4,677,223 shares of the specialty pharmaceutical company’s stock valued at $727,308,000 after purchasing an additional 153,908 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Jazz Pharmaceuticals by 7.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,486,426 shares of the specialty pharmaceutical company’s stock valued at $217,390,000 after purchasing an additional 105,838 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Jazz Pharmaceuticals by 41.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,405,408 shares of the specialty pharmaceutical company’s stock valued at $218,540,000 after purchasing an additional 410,031 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Jazz Pharmaceuticals by 3.5% during the 2nd quarter. Renaissance Technologies LLC now owns 1,201,500 shares of the specialty pharmaceutical company’s stock valued at $186,833,000 after purchasing an additional 40,537 shares during the last quarter. Hedge funds and other institutional investors own 91.30% of the company’s stock.

In other Jazz Pharmaceuticals news, SVP Iain Mcgill sold 8,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $133.42, for a total transaction of $1,067,360.00. Following the completion of the transaction, the senior vice president now owns 28,383 shares in the company, valued at approximately $3,786,859.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $150.00, for a total value of $150,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 10,352 shares of company stock valued at $1,417,763 in the last quarter. Company insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at $136.56 on Tuesday. The firm has a market capitalization of $8,284.56, a PE ratio of 17.34, a price-to-earnings-growth ratio of 0.89 and a beta of 0.98. Jazz Pharmaceuticals PLC has a 52 week low of $99.28 and a 52 week high of $163.75. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.94 and a current ratio of 3.10.

A number of equities analysts recently issued reports on the company. FBR & Co assumed coverage on Jazz Pharmaceuticals in a research note on Thursday, October 19th. They issued a “buy” rating and a $206.00 target price for the company. Wells Fargo & Company restated an “outperform” rating and issued a $177.00 target price (down previously from $178.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, August 10th. Royal Bank Of Canada reduced their target price on Jazz Pharmaceuticals from $210.00 to $195.00 and set an “outperform” rating for the company in a research note on Wednesday, November 8th. Cantor Fitzgerald restated a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Tuesday, August 29th. Finally, Goldman Sachs Group assumed coverage on Jazz Pharmaceuticals in a research note on Thursday, September 28th. They issued a “neutral” rating and a $165.00 target price for the company. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and eighteen have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $180.25.

TRADEMARK VIOLATION NOTICE: “Dynamic Technology Lab Private Ltd Acquires New Holdings in Jazz Pharmaceuticals PLC (JAZZ)” was originally reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/12/05/dynamic-technology-lab-private-ltd-acquires-new-holdings-in-jazz-pharmaceuticals-plc-jazz.html.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.